NW Bio Announces German Early Access and Reimbursement Approvals for DCVax-L

DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator March 10, 2014  Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received approval from the Paul Ehrlich Institute (“PEI”- the FDA of Germany) of a “Hospital Exemption” early access program under Section 4b of the …